Genome Editing in Asia: Can the Region Turn CRISPR Science into Accessible Therapies?
The first approved CRISPR therapy proved that genome editing can work as a medicine. Asia, home to a large share of the world's patients with inherited blood disorders and a fast-growing research base, is now moving from discovery towards the clinic. This article looks at where the region stands, what is holding it back and what to watch next.

Introduction
In late 2023, regulators in the United Kingdom and the United States approved exagamglogene autotemcel (Casgevy), the first medicine built on CRISPR-Cas9 genome editing, for sickle cell disease and later transfusion-dependent beta-thalassaemia. A technology described in the scientific literature just over a decade earlier had become a licensed therapy.
That milestone matters a great deal for Asia. Thalassaemia is common across southern China, Southeast Asia and South Asia, and India carries one of the world's largest burdens of sickle cell disease. The region also has deep scientific capability, a large clinical trial base and a growing biomanufacturing industry. The question is no longer whether genome editing works, but how quickly Asia can turn that science into therapies its own patients can reach.
Beyond Cas9: a broader editing toolbox
First-generation CRISPR-Cas9 cuts both strands of DNA and relies on the cell's own repair machinery. Newer approaches aim to make edits more precise and predictable.
Base editing: changes a single DNA letter without cutting both strands, well suited to correcting point mutations.
Prime editing: writes small insertions, deletions or substitutions using a guide that carries the new sequence.
RNA editing: systems such as Cas13 target RNA rather than DNA, offering reversible effects and new options against viral disease.
Epigenetic editing: switches genes on or off without changing the underlying sequence.
Research groups across the region work on all of these. In Singapore, the A*STAR Genome Institute of Singapore is developing new DNA and RNA editing systems and delivery approaches, and Singapore researchers have shown an AAV-delivered CRISPR-Cas13 approach against the EV-A71 virus.
Clinical momentum across the region
China has become one of the most active places in the world for early genome editing trials, with developers reporting clinical data from CRISPR and base-editing programmes for beta-thalassaemia and other conditions. New rules introduced in 2026 for investigator-initiated cell and gene therapy trials are formalising how these studies move into regulated development.
India has made sickle cell disease a national priority through its National Sickle Cell Anaemia Elimination Mission, launched in 2023, and domestic research institutes are developing their own gene editing approaches with lower cost as an explicit goal.
Japan's conditional, time-limited approval pathway for regenerative medicine products and South Korea's advanced regenerative bio framework both give genetic therapies a defined regulatory route. Singapore regulates them as cell, tissue and gene therapy products, a framework the Health Sciences Authority has operated since 2021.
Delivery is still the hardest problem
Today's approved CRISPR therapy is made ex vivo: a patient's stem cells are collected, edited in a specialised facility and returned after the patient receives conditioning chemotherapy. The process works, but it is long, demanding for patients and expensive to run.
In vivo editing, where the editor is delivered directly into the body, could change that. Lipid nanoparticles have already carried editors to the liver in clinical studies, and in 2025 a personalised base-editing therapy was given to an infant with a rare metabolic disorder in the United States, showing how quickly a bespoke editor can now be designed.
Reaching tissues beyond the liver, including blood stem cells in the body, the muscle and the brain, remains a central research challenge. Viral vectors, new lipid formulations and engineered delivery proteins are all being explored in Asian laboratories.
Manufacturing and cost
Genome editing therapies combine several demanding supply chains: guide RNA and editor production, viral vectors or lipid nanoparticles, and for ex vivo products, patient-specific cell processing under GMP.
Cost is the most visible barrier. Casgevy's list price in the United States is around US$2.2 million per patient, far beyond what most Asian health systems can fund at scale. Lowering it will depend on simpler conditioning regimens, in vivo delivery, automated closed-system cell processing and regional manufacturing capacity.
This is where Asia's biomanufacturing strengths could matter. CDMOs in the region already supply viral vectors, mRNA and cell therapy services, and the same capabilities underpin genome editing products. Analytical methods for off-target effects, editing efficiency and product characterisation will also need to mature alongside manufacturing.
What to watch
Regional approvals: whether and when regulators in Asia approve the first genome editing therapies for thalassaemia and sickle cell disease.
In vivo data: early clinical results from in vivo editing programmes, especially those targeting tissues beyond the liver.
Lower-cost models: domestic programmes in India, China and elsewhere designed for affordability rather than premium pricing.
Safety standards: how regulators set expectations for off-target analysis, long-term follow-up and germline safeguards.
Partnerships: licensing and co-development deals between Asian biotechs, global developers and CDMOs.
The Connexius perspective
Asia combines a large patient need, strong science and a growing ability to manufacture advanced therapies. The region's success in genome editing will be decided less by discovery than by delivery, manufacturing, regulation and price: the steps that turn a working edit into a therapy patients can actually receive.
These are the questions Connexius Genome Editing Asia 2027 will explore in Singapore on 14–15 September 2027, bringing together scientists, biotech and biopharma companies, therapeutic developers, research institutes and technology providers working across CRISPR and next-generation editing, delivery, cell engineering, safety, CMC and clinical translation.
Frequently asked questions
- What is genome editing?
- Genome editing is a set of technologies that make precise changes to DNA or RNA in living cells. CRISPR-Cas systems are the best known, and newer methods include base editing, prime editing and RNA editing.
- What is the difference between ex vivo and in vivo editing?
- Ex vivo editing modifies a patient's cells outside the body before returning them. In vivo editing delivers the editing machinery directly into the body, for example with lipid nanoparticles or viral vectors.
- Why does genome editing matter for Asia?
- Inherited blood disorders such as thalassaemia and sickle cell disease are common across parts of Asia, and the region has a large research, clinical trial and biomanufacturing base that could support more affordable therapies.
- What is base editing?
- Base editing changes a single DNA letter without cutting both strands of the DNA, which makes it well suited to correcting the point mutations behind many genetic diseases.